1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Kidney protection with the radical scavenger α1-microglobulin (A1m) during peptide receptor radionuclide and radioligand therapy
(
- Contribution to journal › Article
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
- 2016
-
Mark
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2
(
- Contribution to journal › Article
- 2015
-
Mark
Intratherapeutic Biokinetic Measurements, Dosimetry Parameters Estimate, and Monitoring Treatment Efficacy using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy.
(
- Contribution to journal › Article
-
Mark
Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution.
(
- Contribution to journal › Article
- 2014
-
Mark
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a In-111-radiolabelled monoclonal antibody, 11B6
(
- Contribution to journal › Article
-
Mark
Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer.
(
- Contribution to journal › Article